Flu SensDx - 93.7 % sensitivity and 97.5 % specificity

Product information

This product was launched in Poland in the autumn of 2019, and is already used at 100 doctors' offices and hospitals in the country. In the flu season 2019/2020, more than 10,000 tests were performed. The Flu SensDx influenza test was evaluated by an independent CRO * in four different geographical areas. The results of the 118 tests showed 93.7 % sensitivity and 97.5 % specificity. Optimization of Mobi SensDx's learning algorithm of the diagnostic platform will continuously improve the results. The product is available in Scandinavia in the early third quarter of 2020.

* A CRO (Clinical Research Organization) is a private company that undertakes to conduct clinical research for academia, the pharmaceutical and biotechnology industries in connection with the testing of medicines and medical equipment. It is assumed that a CRO meets all international established requirements and general ethical rules in connection with research.